Health Guidance

Global Weight Loss
and Diet Management (2009 – 2014)

Report description

The global weight management market continues to grow despite the current downturn in the global economy and is estimated to reach US$586 billion in 2014 from about US$363 billion in 2009. The driving force for the global weight management market is the dramatic increase in the obese population. Sedentary but fast paced lifestyle and consumption of high calorie and under-nutritious food has contributed to the rising number of obese and overweight people. These are the main target segment of the weight management market. ( http://www.bharatbook.com/Market-Research-Reports/Global-Weight-Loss-and-Diet-Management.html )

Consumer focus on improving quality of life has increased the sale of products that claim to manage or reduce weight. The existing players in the food and beverage (F&B) market, as well as in the drugs and supplement market, have accordingly expanded their market scope to increase revenues by targeting this segment. Marginal weight loss can be attained through personal efforts, however, overweight and obesity are increasingly becoming a concern that require the intervention of professionals and other service providers. This is expanding the scope of weight management services market.

Continue reading ‘Bharatbook.com : Global Weight Loss and Diet Management’ »

Pfizer’s novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug’s analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, it expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy. ( http://www.bharatbook.com/detail.asp?id=130154&rt=Stakeholder-Insight-Osteoarthritis-Drug-development-lags-behind-rising-osteoarthritis-population.html )

Pfizer has announced positive results from three Phase II trials in pain at the American Academy of Pain Medicine’s 26th Annual Meeting. The randomized, double-blind, placebo-controlled six-week trials in patients with chronic low back pain (CLBP) and interstitial cystitis receiving a single intravenous infusion of tanezumab (200mcg/kg) met their primary endpoints of significantly superior pain relief over placebo. Continue reading ‘Pfizer's novel NGF pain drug is potential game changer’ »

Argenta-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Argenta-Company Report’ »

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs. ( http://www.bharatbook.com/detail.asp?id=68637&rt=F-Hoffmann-La-Roche-Ltd-PharmaVitae-Profile.html )

Roche has invested roughly CHF190m ($183m) at two production sites to manufacture devices that will allow patients to self-administer a subcutaneous formulation of Herceptin (trastuzumab; Roche/Genentech/Chugai). Continue reading ‘Roche: novel Herceptin formulation promises greater convenience’ »

Incoming search terms:

• herceptin indian manufacturers

Astellas Pharma Canada, Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Astellas Pharma Canada, Inc.-Company Report’ »

Oncology Market Leaders – Analyses and Outlook – 2010-2025

Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, anti-cancer drug sales exceeded $50bn worldwide in 2009. The oncology drug market has grown impressively, driven by rising disease prevalence, expanding patient populations and technological advances, especially in biomolecular medicine. Current treatments are better-tolerated, more- effective and more-commercially-successful than ever before, our latest report shows. ( http://www.bharatbook.com/detail.asp?id=132312&rt=Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html )

The aging of populations, lifestyle changes in the developing world, together with significant advances in pharmacotherapy and diagnostics, will drive the cancer treatments market from 2010 onwards. Increasing disease prevalence and a strong R&D pipeline make the anti-cancer sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report, Oncology Market Leaders – Analyses and Outlook – 2010-2025, explains why and to what extent, revealing where the most-exciting and lucrative developments will lie from 2010 onwards. There, you will find detailed sales predictions and supporting discussions. Continue reading ‘Comprehensive Analysis Of The Oncology Market Sector’ »

The report provides market landscape, competitive landscape and market trends information on four ophthalmic devices market categories – cataract surgery devices, refractive surgery devices, vision care, and ophthalmic diagnostic equipment. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.( http://www.bharatbook.com/detail.asp?id=133653&rt=The-Future-of-Ophthalmic-Devices-Market-Forecasts-and-Growth-Opportunities-to-2016-The-Vision-Care-Segment-Emerges-as-a-Key-Revenue-Generator.html )

The Global Ophthalmic Devices Market to Reach $28 billion by 2016The global ophthalmic devices market is forecast to reach $28 billion by 2016 with a Compound Annual Growth Rate (CAGR) of 2.5% from 2009-2016. The market is expected to be driven by a huge population suffering from vision problems, the availability of reimbursement for a majority of the devices and surgeries and the direct to consumer approach of the companies. The aging population is also an important growth driver for the market. The availability and accessibility of treatment for a majority of vision problems is also leading to increased patient demand and a subsequent growth in the market. This report provides key data, information and analysis on the global ophthalmic devices market.

The US to Continue to be the Biggest Ophthalmic Devices Market
The US is the biggest market for ophthalmic devices, contributing 26% towards the global market in 2009, and this contribution is expected to increase to 27% in 2016. The US ophthalmic devices market was valued at $6 billion in 2009 and is forecast to grow at a CAGR of 3.4% to reach $7.6 billion in 2016. The market is expected to be driven by the high prevalence of vision problems, the increasing contribution of employees and employers for vision care coverage and the availability and easy accessibility of the latest medical interventions for affected patients. Continue reading ‘Vision Care Market Remains The Largest Category In The Global Ophthalmic Devices Market’ »

Avexa Limited-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and biomedical companies.

Scope of the reports

Accessing accurate, current and comprehensive content on private companies can be challenging and Life Science Analytics has created a suite of reports that deliver the latest information on over 1,000 private firms. Each report provides a corporate overview and business description along with detail on the company’s management team and its products. . Continue reading ‘Avexa Limited-Company Report’ »

Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth

Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population still has high unmet needs. Some key oncology companies have entered the leukemias market fairly recently while others are pursuing late-phase development in this indication, hoping to exploit the commercial potential of patient subgroups underserved by existing treatment options. ( http://www.bharatbook.com/detail.asp?id=134190&rt=Pipeline-Insight-Leukemias-Underserved-patient-populations-offer-potential-for-market-growth.html ) Continue reading ‘Pipeline Insight Leukemias Underserved Patient Populations Offer Potential For Market Growth’ »

EASD 2009: Lantus defended amid allegations of increased cancer risk

It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )

Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.

It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »